The VAR2CSA protein is a vaccine candidate against PM due to its surface localisation, function as an adhesin for placental CSA and its role in immunity against PM [11, [20] [21] [22] [23] [24] [25] [26] [27] . Although the fulllength protein can be produced, a vaccine based on a single domain is more likely to be feasible, due to the complexity and size of the antigen. To analyze if the immune responses towards singledomains and the full-length protein were comparable, we tested all single VAR2CSA domains as well as the full-length protein in three different animal species.